News

Epigenic Therapeutics Secures $60 Million to Enhance Therapies

Epigenic Therapeutics Secures $60 Million to Enhance Therapies

Significance of Recent Financing for Epigenic Therapeutics

Epigenic Therapeutics, a pioneering company focused on innovative gene modulation therapies, has successfully completed a significant financing round. This funding, amounting to $60 million, was led by Lapam Capital and included continued support from existing investors as well as interest from new investors. This investment plays a crucial role in propelling the clinical development of promising treatments and technologies aimed at addressing chronic health conditions.

Optimizing Development of Epigenetic Medicines

The primary objective of this funding is to further the clinical development of EPI-003, a promising candidate aimed at providing a functional cure for chronic hepatitis B. Alongside this, funding will support EPI-001 for the treatment of hypercholesterolemia. These advancements showcase Epigenic’s commitment to developing effective therapies that target prevalent health challenges.

Innovative Technology Platforms at Epigenic

One of the standout features of Epigenic is its proprietary EPIREG™ technology platform. This cutting-edge platform enables specific and sustained silencing of target genes through precise mechanisms such as DNA methylation and histone modification. Unlike traditional gene-editing tools, which pose various safety risks, EPIREG™ represents a revolutionary approach to therapeutics, significantly enhancing patient safety in chronic disease treatment.

Expanding Delivery Mechanisms

In addition to EPIREG™, Epigenic has developed the EpiTax™ platform, an advanced delivery system designed to precisely deliver therapeutic agents to the liver and other organs. This innovation broadens EPIREG™'s potential applications, enriching Epigenic's overall technological framework and positioning it competitively within the biotechnology landscape.

Empowering Epigenetic Medicine Through AI

The AIAID™ platform, another novel system developed by Epigenic, streamlines the design and modulation processes of epigenetic treatments. This platform integrates a self-developed model that supports core epigenetic data analysis and decision-making. Utilizing a virtual lab concept, AIAID™ facilitates tasks essential for research advancement, including target selection, sgRNA design, and the evaluation of potential therapies.

Leadership and Vision

Dr. Bob Zhang, the CEO and Co-founder of Epigenic Therapeutics, expressed gratitude toward the investors for their trust and support. Since its establishment, the company has achieved significant milestones in advancing epigenetic technologies and remains focused on delivering safe and effective therapies to patients as quickly as possible. Notably, industry leaders recognize Epigenic's potential for fostering innovation in epigenetic therapies.

Community Support from Investors

Mr. Zhihua Yu, Chairman of Lapam Capital, acknowledged the unique advantages that Epigenic brings to the field of drug development. The technological foundation established by EPIREG™ and EpiTax™ positions the firm for future breakthroughs in clinical trials, further allowing them to solidify their presence in the innovative healthcare space.

About Epigenic Therapeutics

As a forefront biotechnology company established in 2021, Epigenic Therapeutics is committed to developing next-generation gene modulation therapies. The company focuses on leveraging epigenetic regulation to treat a variety of diseases, and develops several promising product candidates aimed at metabolic, cardiovascular, and autoimmune diseases.

About Lapam Capital

Lapam Capital is a leading venture capital firm that specializes in the biomedical sector. The firm has managed multiple funds, focusing on innovative pharmaceuticals and medical devices. Their strategy emphasizes supporting early to mid-stage companies, thus fostering growth within the biotech sector.

Frequently Asked Questions

What is the purpose of the recent financing for Epigenic Therapeutics?

The financing aims to support the clinical development of EPI-003 and EPI-001, crucial treatments targeting hepatitis B and hypercholesterolemia.

What technologies are being developed at Epigenic Therapeutics?

Epigenic is advancing technologies like EPIREG™ for gene modulation and EpiTax™ for targeted drug delivery, enhancing safety and efficacy in treatments.

Who are the key investors in Epigenic Therapeutics?

The recent funding round was led by Lapam Capital, with participation from existing investors such as Qiming Venture Partners and OrbiMed, along with new investors.

What challenges does Epigenic aim to address?

Epigenic focuses on prevalent chronic diseases, intending to develop safe and effective therapies while mitigating safety concerns associated with traditional gene editing.

How can I learn more about Epigenic Therapeutics?

For further information, individuals can explore Epigenic's website to understand their mission, technologies, and ongoing projects.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 232

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 128

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 187

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 217

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 302

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 183

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 119

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 154

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 169

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 187

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading

Top 5 Most Recently Viewed Articles

FarmHouse Fresh Celebrates 20 Years of Skincare Innovation

Updated Category News Views 294

Celebrating Two Decades of Skincare Excellence FarmHouse Fresh® is excited to celebrate its 20th anniversary, a significant milestone in its journey of transforming skincare routines and enriching lives through animal rescue. Over the last two decades, the brand has become renowned for its unique farm-to-table skincare products, drawing inspiration from nature's best...

Continue Reading
Rigetti Computing and Quanta Computer Join Forces for Quantum Advancements

Updated Category News Views 437

Exciting Collaboration in Quantum Technology Rigetti Computing, Inc. (NASDAQ: RGTI), a leader in quantum-classical computing, has forged a powerful collaboration with Quanta Computer Inc., a major player based in Taiwan. This strategic agreement signifies a strong commitment from both companies to push the boundaries of superconducting quantum computing, with a shared...

Continue Reading
Crucial Update for Match Group, Inc. Investors: Act Now

Updated Category News Views 189

Update on Match Group, Inc.'s Ongoing Class Action In recent developments, investors holding shares in Match Group, Inc. (NASDAQ: MTCH) are reminded of their rights as a class action has been initiated on behalf of those who purchased or acquired MTCH securities during the designated period. This lawsuit follows significant stockholder losses, particularly pertaining to...

Continue Reading
Home Insurance Gaps: Risky Assumptions Uncovered

Updated Category News Views 214

Unseen Threats to Homeownership Safety Liability gaps in insurance are like those stubborn stains on the carpet you keep missing—nearly invisible until you're flat on your face. In Alpharetta and Fulton County, homes aren't as secure from financial pitfalls as their charming façades suggest. So, what's the danger that folks are glossing over here? Hidden Dangers of...

Continue Reading
Stock Market Movements: Energy Surges as Instil Bio Drops

Updated Category News Views 144

Stock Market Overview The latest trading session produced varied results for U.S. stocks, creating a mixed bag for investors. The Nasdaq Composite dipped by about 1%. In contrast, the Dow Jones Industrial Average rose by 0.29%, reaching a noteworthy 41,512.19. On the other hand, the S&P 500 experienced a slight decline of 0.24%, settling at 5,612.35. Sector Performance...

Continue Reading